VEOZAH Drug Patent Profile
✉ Email this page to a colleague
When do Veozah patents expire, and what generic alternatives are available?
Veozah is a drug marketed by Astellas and is included in one NDA. There are four patents protecting this drug.
This drug has sixty patent family members in twenty-six countries.
The generic ingredient in VEOZAH is fezolinetant. One supplier is listed for this compound. Additional details are available on the fezolinetant profile page.
DrugPatentWatch® Generic Entry Outlook for Veozah
Veozah will be eligible for patent challenges on May 12, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 12, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VEOZAH
International Patents: | 60 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for VEOZAH |
What excipients (inactive ingredients) are in VEOZAH? | VEOZAH excipients list |
DailyMed Link: | VEOZAH at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VEOZAH
Generic Entry Date for VEOZAH*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for VEOZAH
US Patents and Regulatory Information for VEOZAH
VEOZAH is protected by four US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VEOZAH is ⤷ Try a Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VEOZAH
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE WITH MENOPAUSE
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MODERATE TO SEVERE VASOMETER SYMPTOMS DUE TO MENOPAUSE
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MODERATE TO SEVERE VASOMETER SYMPTOMS DUE TO MENOPAUSE
FDA Regulatory Exclusivity protecting VEOZAH
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | VEOZAH | fezolinetant | TABLET;ORAL | 216578-001 | May 12, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Astellas | VEOZAH | fezolinetant | TABLET;ORAL | 216578-001 | May 12, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Astellas | VEOZAH | fezolinetant | TABLET;ORAL | 216578-001 | May 12, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Astellas | VEOZAH | fezolinetant | TABLET;ORAL | 216578-001 | May 12, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Astellas | VEOZAH | fezolinetant | TABLET;ORAL | 216578-001 | May 12, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VEOZAH
See the table below for patents covering VEOZAH around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 2948455 | ⤷ Try a Trial | |
Cyprus | 1119576 | ⤷ Try a Trial | |
Lithuania | 2552920 | ⤷ Try a Trial | |
Japan | 2018118988 | 選択的NK−3受容体拮抗薬としての新規なN−アシル−(3位置換)−(8位置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、医薬組成物、NK−3受容体媒介性障害における使用方法 (N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS) | ⤷ Try a Trial |
Singapore | 11201508005X | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | ⤷ Try a Trial |
Hong Kong | 1214816 | 作為選擇性 受體拮抗劑的新型 -酰基- -取代 -取代 -二氫- 三唑並 吡嗪、藥物組合物、用於 受體介導的病症的方法 (NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS NK-3 N--(3-)-(8-)-56-- [124][43-A] NK-3) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |